ONCE-DAILY INHALED UMECLIDINIUM/VILANTEROL COMBINATION THERAPY COMPARED WITH PLACEBO ON EXACERBATIONS IN CHINESE PATIENTS WITH COPD

被引：0
|
作者：
Zheng, Jinping [1 ]
Goh, Aik [2 ]
Huang, Chunchen [2 ]
Luo, Xian [2 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 1, Natl Clin Res Ctr Resp Dis, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China
[2] GlaxoSmithKline, Shanghai, Peoples R China
来源：
RESPIROLOGY | 2017年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AO110
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [31] 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study
    David A. Lipson
    Ruby Birk
    Noushin Brealey
    Chang-Qing Zhu
    Advances in Therapy, 2020, 37 : 4894 - 4909
  • [32] ASTHMA-RELATED EXACERBATIONS AND SABA USE ASSOCIATED WITH ONCE-DAILY FLUTICASONE FUROATE/VILANTEROL COMPARED TO TWICE-DAILY BUDESONIDE/FORMOTEROL
    Averell, C.
    Germain, G.
    Laliberte, F.
    Duh, M.
    Lima, R.
    Slade, D.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S33 - S33
  • [33] Onset Of Effect Of Umeclidinium/vilanterol Compared With Other Maintenance Therapies In Patients With COPD
    Kalberg, C.
    Brooks, J.
    Worsley, S.
    Harris, S.
    Zvarich, M.
    Church, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [34] The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroub of Patients from China with Symptomatic COPO at Risk of Exacerbations (FULFIL Trial)
    Zheng, Jinping
    Zhong, Nanshan
    Wang, Changzheng
    Huan, Yijiang
    Chen, Ping
    Wang, Limin
    Hui, Fuxin
    Zhao, Li
    Wang, Haoyan
    Luo, Linda
    Du, Xin
    Goh, Aik Han
    Lipson, David A.
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 15 (04) : 334 - 340
  • [35] 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study
    Lipson, David A.
    Birk, Ruby
    Brealey, Noushin
    Zhu, Chang-Qing
    ADVANCES IN THERAPY, 2020, 37 (12) : 4894 - 4909
  • [36] Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients
    Miravitlles, Marc
    Galdiz, Juan B.
    Huerta, Alicia
    Villacampa, Alba
    Carcedo, David
    Garcia-Rio, Francisco
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2016, 11 : 123 - 132
  • [37] Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD
    Crim, Courtney
    Dransfield, Mark T.
    Bourbeau, Jean
    Jones, Paul W.
    Hanania, Nicola A.
    Mahler, Donald A.
    Vestbo, Jorgen
    Wachtel, Andrew
    Martinez, Fernando J.
    Barnhart, Frank
    Lettis, Sally
    Calverley, Peter M. A.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 (01) : 27 - 34
  • [38] Real-World Effectiveness of Fluticasone Furoate/ Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial
    Beeh, Kai -Michael
    Scheithe, Karl
    Schmutzler, Heike
    Krueger, Saskia
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2024, 19 : 205 - 216
  • [39] Exploring the Comparative Efficacy and Safety of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol in Moderate Symptomatic COPD: A Randomized Non-Inferiority Crossover Trial
    Feldman, Gregory
    Sousa, Ana
    Lipson, David
    Tombs, Lee
    Compton, Chris
    Alcazar, Bernardino
    CHEST, 2017, 152 (04) : 737A - 737A
  • [40] Once-daily fluticasone furoate/vilanterol vs once-daily fluticasone furoate in patients with asthma aged 5 to 17 years
    Bareille, Philippe
    Forth, Richard
    Imber, Varsha
    Bondarenko, Irina
    Michaud, Arthur
    Majorek-Olechowska, Bernadetta
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (05)
12345